Nanexa participated in PODD (Partnership Opportunities in Drug Delivery) in Boston earlier this week. PODD is one of Nanexa’s most important yearly conferences, since it is focused on drug delivery and has global big pharma companies participating.

The CEO of Nanexa, David Westberg, presented the PharmaShell® technology at the conference, specifically focusing on the NEX-22 project. NEX-22 is Nanexa’s long acting injectable formulation of the GLP-1 analog liraglutide with PharmaShell, for treatment of type 2 diabetes with once monthly administration. Liraglutide is a compound developed and marketed by Novo Nordisk for daily injections and with the US patent expired earlier this year.

In the presentation program at PODD, several companies addressed the market for GLP-1 treatment in type 2 diabetes and obesity. In particular the need for a less frequent administered product, such a once monthly product, was expressed both by Novo Nordisk and Eli Lilly. Mainly for patient convenience and adherence to prescribed treatment, but also to improve the situation from an environmental perspective.

Besides the well-attended presentation held by Nanexa, Nanexa had specific meetings with several of the big pharma companies in the diabetes- and obesity fields and other indication areas where depot formulation is needed.

” It is very exciting to be representing Nanexa at these events and have the possibility to, as the only company, present an ongoing clinical project with a long acting injectable GLP-1 treatment. The interest in NEX-22 has definitely increased even more, as well as the interest in PharmaShell as drug delivery technology within other therapeutic indications. It will be very interesting when we can present results from our NEX-22 clinical study later this year and then also can follow-up with the companies that have shown a specific interest in the project” says David Westberg, CEO.